急性冠状动脉综合征患者早期应用不同剂量的阿托伐他汀的有效性及安全性对比

目的：观察急性冠状动脉综合征（ ACS）早期应用不同剂量的阿托伐他汀的临床疗效及安全性。方法选择临床确诊为ACS的患者共80例,随机分为10 mg组和40 mg组,每晚服药1次,观察4周、12周后的血脂和高敏C-反应蛋白（ hsCRP）,随访3个月内的不良反应及心脏事件的发生率。结果①两组服药后4周、12周的总胆固醇（ TC）、低密度脂蛋白（LDL-C）、hsCRp水平40 mg组比10 mg组降低更明显,两组比较差异有统计学意义,P〈0.05。②两组均无严重不良反应。结论 ACS早期应用40 mg阿托伐他汀能够更有效地降低TC和LDL-C水平,降低炎症因子,且具有良好的安全性。

Comparing the efficacy and safety of different doses in patients with early acute coronary syndrome of atorvastatin

Objective To observe the effect of acute coronary syndrome （ ACS） clinical efficacy and safety of early appli-cation of different doses of atorvastatin. Methods the clinical diagnosis of acute coronary syndrome patients with a total of 80 ca-ses, were randomly divided into 10mg group and 40m group, nightly medication time, blood lipid and high sensitive C- reactive protein in 4 weeks, 12 weeks （ hsCRP） , the incidence of adverse reactions and cardiac events were followed up for 3 months the. Results ①Two groups after 4 weeks, 12 weeks of total cholesterol, low density lipoprotein, the level of hsCRp 40 mg in group mg than in group mg decreased more significantly in 10 mg, there was significant difference between two groups （P〈0. 05）. ②The two groups had no serious adverse reactions. Conclusion Acute coronary syndrome （ACS） 40m g early application atorvas-tatin can effectively reduce the total cholesterol （ TC） and low density lipoprotein cholesterol （ LDL-C） levels, reduce inflammatory factors, and has a good safety.